All Stories

  1. A Complex Neurodevelopmental Phenotype Resembling a Chromatinopathy With Concurrent 7p Duplication and 10p Deletion Involving ZMYND11 : A Case Report ...
  2. A Rare Combination of High‐Affinity Hemoglobin, Non‐Transfusion‐Dependent Thalassemia (Αlpha‐Triplication and Codon 39 Mutation), and Hereditary Stomatocytosis
  3. Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report
  4. Additive effect of multiple genetic variants in SEC23B and PIEZO1 on iron metabolism dyshomeostasis in hereditary anemias
  5. Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report
  6. A novel pathogenic variant causing POU3F3-related neurodevelopmental disorder in a child presenting with infantile epileptic spasms syndrome: Expanding the epileptic phenotype
  7. Label-free holographic microscopy of red blood cells to identify hereditary anaemias
  8. The evolving landscape of hereditary stomatocytosis
  9. Mitapivat metabolically reprograms human β-thalassemic erythroblasts, increasing their responsiveness to oxidation
  10. COVID- 19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet
  11. Myoclonic reflex and non‐reflex seizures in a female child with Coffin–Lowry syndrome: Clinical vignette
  12. P2 Receptor Antagonists Rescue Defective Heme Content in an In Vitro SLC25A38-Associated Congenital Sideroblastic Anemia Cell Model
  13. RAS signaling pathway is essential in regulating PIEZO1‐mediated hepatic iron overload in dehydrated hereditary stomatocytosis
  14. Relevance of the E756del common variant in the PIEZO1 gene for haemolytic anaemia and hepatic iron overload
  15. Genotype–Phenotype Correlation of GNAS Gene: Review and Disease Management of a Hotspot Mutation
  16. Towards a Deep Learning Approach to Discriminate Hereditary Anemias
  17. A Novel De Novo STAG1 Variant in Monozygotic Twins with Neurodevelopmental Disorder: New Insights in Clinical Heterogeneity
  18. Hereditary Hemolytic Anemia Due to PIEZO1 Red Blood Cell Membrane Defect
  19. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia
  20. Targeting ATP2B1 impairs PI3K/Akt/FOXO signaling and reduces SARS-COV-2 infection and replication
  21. Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features
  22. Updates on clinical and laboratory aspects of hereditary dyserythropoietic anemias
  23. Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients
  24. A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death
  25. First Case of a Dominant De Novo SEC23A Mutation with Neurological and Psychiatric Features: New Insights into Cranio-Lenticulo-Sutural Dysplasia with Literature Review
  26. A stepwise diagnostic approach for undiagnosed Anemia in children: A model for low-middle income country
  27. Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis
  28. Hierarchical learning approaches for improving label-free single-cell classification in holographic microscopy
  29. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice
  30. Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder
  31. Proteome alterations in erythrocytes with PIEZO1 gain-of-function mutations
  32. Resources and tools for rare disease variant interpretation
  33. One gene, two opposite phenotypes: a case report of hereditary anemia due to a loss-of-function variant in the <i>EPAS1</i> gene
  34. Coinheritance of PIEZO1 variants and multi‐locus red blood cell defects account for the symptomatic phenotype in beta‐thalassemia carriers
  35. Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency
  36. In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell–Related Injury
  37. Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in M-thalassemic mice
  38. PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes
  39. Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features
  40. Evaluation of the Main Regulators of Systemic Iron Homeostasis in Pyruvate Kinase Deficiency
  41. Clinical exome-based panel testing for medically actionable secondary findings in a cohort of 383 Italian participants
  42. An explainable model of host genetic interactions linked to COVID-19 severity
  43. Targeting ATP2B1 impairs PI3K/Akt/Fox-O3 signaling and reduces SARS-COV-2 replication in vivo
  44. Rheumatoid arthritis and osteogenesis imperfecta: is there a genetic causal association?
  45. A first update on mapping the human genetic architecture of COVID-19
  46. Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals
  47. The use of next‐generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH/EHA Good Practice Paper*
  48. The Use of Next-generation Sequencing in the Diagnosis of Rare Inherited Anaemias: A Joint BSH/EHA Good Practice Paper
  49. Hereditary anemia caused by multilocus inheritance of <i>PIEZO1</i>, <i>SLC4A1</i> and <i>ABCB6</i> mutations: a diagnostic and therapeutic challenge
  50. Differential diagnosis of hereditary anemias from a fraction of blood drop by digital holography and hierarchical machine learning
  51. Whole-genome sequencing reveals host factors underlying critical COVID-19
  52. Novel Insights and Future Perspective in Iron Metabolism and Anemia
  53. SEC23B Loss-of-Function Suppresses Hepcidin Expression by Impairing Glycosylation Pathway in Human Hepatic Cells
  54. Editorial: Genetics and Genomics of Red Blood Cells
  55. The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males
  56. Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients
  57. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity
  58. The frameshift Leu220Phefs*2 variant in KRIT1 accounts for early acute bleeding in patients affected by cerebral cavernous malformation
  59. Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia
  60. Mapping the human genetic architecture of COVID-19: an update
  61. SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues
  62. Recommendations for diagnosis and treatment of methemoglobinemia
  63. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity
  64. The Serum Metabolome of Moderate and Severe COVID-19 Patients Reflects Possible Liver Alterations Involving Carbon and Nitrogen Metabolism
  65. Mapping the human genetic architecture of COVID-19
  66. The EHA Research Roadmap: Anemias
  67. C9orf72 Intermediate Repeats Confer Genetic Risk for Severe COVID-19 Pneumonia Independently of Age
  68. Complex Modes of Inheritance in Hereditary Red Blood Cell Disorders: A Case Series Study of 155 Patients
  69. The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy
  70. SELP Asp603Asn and severe thrombosis in COVID-19 males: implication for anti P-selectin monoclonal antibodies treatment
  71. Regulatory Noncoding and Predicted Pathogenic Coding Variants of CCR5 Predispose to Severe COVID-19
  72. Protective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women
  73. Recommendations for pregnancy in Fanconi anemia
  74. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model
  75. Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19
  76. The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males
  77. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study
  78. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males
  79. Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19
  80. Post-Mendelian genetic model in COVID-19
  81. Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research
  82. Common Variants at 21q22.3 Locus Influence <i>MX1</i> Gene Expression and Susceptibility to Severe COVID-19
  83. Genetics and Genomics Approaches for Diagnosis and Research Into Hereditary Anemias
  84. Common variants at 21q22.3 locus influenceMX1gene expression and susceptibility to severe COVID-19
  85. Genetic mechanisms of critical illness in Covid-19
  86. Inherited microcytic anemias
  87. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males
  88. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in males
  89. Congenital dyserythropoietic anemias
  90. Uridine treatment normalizes the congenital dyserythropoietic anemia type II ‐like hematological phenotype in a patient with homozygous mutation in the CAD gene
  91. Corrigendum: Characterization of Two Cases of Congenital Dyserythropoietic Anemia Type I Shed Light on the Uncharacterized C15orf41 Protein
  92. RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway
  93. Genetic Analysis of the Coronavirus SARS-CoV-2 Host Protease TMPRSS2 in Different Populations
  94. Recommendations for Pregnancy in Rare Inherited Anemias
  95. Employing a Systematic Approach to Biobanking and Analyzing Clinical and Genetic Data for Advancing COVID-19 Research
  96. Apparent recessive inheritance of sideroblastic anemia type 2 due to uniparental isodisomy at the SLC25A38 locus
  97. A novel PIEZO1 mutation in a patient with dehydrated hereditary stomatocytosis: a case report and a brief review of literature
  98. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population
  99. Bimodal strategy for excellent audiological rehabilitation in a subject with a novel nonsense mutation of the SLC26A4 gene: A case report
  100. Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations
  101. Shorter Androgen Receptor PolyQ Alleles Protect Against Life-Threatening COVID-19 Disease in Males
  102. Gain‐of‐function mutations in PIEZO1 directly impair hepatic iron metabolism via the inhibition of the BMP/SMADs pathway
  103. Hematopoietic Stem Cell Transplantation in Congenital Dyserythropetic Anemia Type II: A Case Report and Review of the Literature
  104. CoDysAn: A Telemedicine Tool to Improve Awareness and Diagnosis for Patients With Congenital Dyserythropoietic Anemia
  105. The BMP‐SMAD pathway mediates the impaired hepatic iron metabolism associated with the ERFE‐A260S variant
  106. Advances in understanding the pathogenesis of red cell membrane disorders
  107. Diagnostic decision support tool for anemias based on label-free holographic imaging
  108. Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition
  109. Hereditary spherocytosis and allied disorders
  110. Characterization of Two Cases of Congenital Dyserythropoietic Anemia Type I Shed Light on the Uncharacterized C15orf41 Protein
  111. PIEZO1 Hypomorphic Variants in Congenital Lymphatic Dysplasia Cause Shape and Hydration Alterations of Red Blood Cells
  112. Anaemias diagnosis by label-free quantitative phase imaging
  113. Genotype-phenotype correlation and risk stratification in a cohort of 123 hereditary stomatocytosis patients
  114. Label-Free Optical Marker for Red-Blood-Cell Phenotyping of Inherited Anemias
  115. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias
  116. PIEZO1-R1864H rare variant accounts for a genetic phenotype-modifier role in dehydrated hereditary stomatocytosis
  117. Hereditary stomatocytosis: An underdiagnosed condition
  118. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients
  119. Targeted next generation sequencing identifies a novel β-spectrin gene mutation A2059P in two Omani children with hereditary pyropoikilocytosis
  120. GATA1 erythroid-specific regulation of SEC23B expression and its implication in the pathogenesis of congenital dyserythropoietic anemia type II
  121. Recommendations regarding splenectomy in hereditary hemolytic anemias
  122. New insights on hereditary erythrocyte membrane defects
  123. Increased levels of ERFE-encoding FAM132B in patients with congenital dyserythropoietic anemia type II
  124. Functional characterization of novel ABCB6 mutations and their clinical implications in familial pseudohyperkalemia
  125. Next generation research and therapy in red blood cell diseases
  126. The European Hematology Association Roadmap for European Hematology Research: a consensus document
  127. Diagnosis and management of congenital dyserythropoietic anemias
  128. Novel Gardos channel mutations linked to dehydrated hereditary stomatocytosis (xerocytosis)
  129. Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients
  130. Red cells in post-genomic era: impact of personalized medicine in the treatment of anemias
  131. Congenital erythropoietic porphyria linked to GATA1-R216W mutation: challenges for diagnosis
  132. Retrospective cohort study of 205 cases with congenital dyserythropoietic anemia type II: Definition of clinical and molecular spectrum and identification of new diagnostic scores
  133. Successful hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia type II
  134. Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy
  135. Corrigendum
  136. Hypomorphic mutations of SEC23B gene account for mild phenotypes of congenital dyserythropoietic anemia type II
  137. Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1
  138. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility
  139. Missense mutations in the ABCB6 transporter cause dominant familialpseudohyperkalemia
  140. Clinical aspects and pathogenesis of congenital dyserythropoietic anemias: from morphology to molecular approach
  141. Inherited hematological disorders due to defects in coat protein (COP)II complex
  142. Integration of Pharmacogenetics and Pharmacogenomics in Drug Development: Implications for Regulatory and Medical Decision Making in Pediatric Diseases
  143. A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency
  144. Two founder mutations in the SEC23B gene account for the relatively high frequency of CDA II in the Italian population
  145. Congenital dyserythropoietic anemias
  146. A Dyserythropoietic Anemia Associated with Homozygous Hb Plasencia [α125(H8)Leu→Arg (α2)] (HBA2:c.377T>G), A Variant with an Unstable α Chain
  147. Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives
  148. Mutational spectrum in congenital dyserythropoietic anemia type II: Identification of 19 novel variants in SEC23B gene
  149. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness
  150. Regulation of divalent metal transporter 1 (DMT1) non-IRE isoform by the microRNA Let-7d in erythroid cells
  151. Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness
  152. Molecular analysis of 42 patients with congenital dyserythropoietic anemia type II: new mutations in the SEC23B gene and a search for a genotype-phenotype relationship
  153. Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II
  154. A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population
  155. SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells
  156. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C
  157. Comparative Proteomic Expression Profile in All-trans Retinoic Acid Differentiated Neuroblastoma Cell Line
  158. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus–related chronic hepatitis: Insulin resistance and response to antiviral therapy